Aktiesnakken — August 2011
-
novo skal hvert år have dobbelt digit growth for at forsvare deres mcap, men det er mixed. De opjusterer forventninger til helåret
-
men mr. market kigger nok mere på dette kvartal og sige skuffende...
-
bava får godt nok huk lige nu, hvad sker i der i den?
-
aah nedjustering fra konkurrent..
-
Bava har nu også fået temmelig mange tæsk så nu prøver man med en lille klat i bava
-
ja pandora og biotek har jo intet med hinanden at gøre
-
det kunne godt værre at man skulle købe DNDN..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind